Jasper Therapeutics, Inc. (JSPR) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Jasper Therapeutics, Inc. (JSPR) Earnings Overview
As of June 13, 2026, Jasper Therapeutics, Inc. (JSPR) reported trailing twelve-month net income of -$56M, reflecting +19.2% year-over-year growth. The company earned $-3.63 per diluted share over the past four quarters.
Looking at the long-term picture, JSPR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2019.
Jasper Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including BEAM (-$65M net income, -57.2% margin), EDIT (-$109M net income, -395.0% margin), CRSP (-$569M net income, -16569.8% margin), JSPR has comparable earnings metrics. Compare JSPR vs BEAM →
JSPR Earnings vs Peers
Earnings metrics vs comparable public companies
JSPR Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$76M | -6.4% | -$81M | $-3.95 | - | - |
| 2024 | -$71M | -10.6% | -$76M | $-4.89 | - | - |
| 2023 | -$64M | -71.1% | -$69M | $-6.18 | - | - |
| 2022 | -$38M | -23.0% | -$51M | $-10.33 | - | - |
| 2021 | -$31M | +3.3% | -$37M | $-26.89 | - | - |
| 2020 | -$32M | -535.0% | -$21M | $-183.08 | - | - |
| 2019 | -$5M | - | -$5M | $0.00 | - | - |
Download Data
Export JSPR earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in JSPR back in 2019?
Total return with dividends reinvested · 7+ years of data
Calculate ReturnsHow much would $100/month in JSPR be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs JSPR Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationJSPR vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowJSPR — Frequently Asked Questions
Quick answers to the most common questions about buying JSPR stock.
What is JSPR earnings per share (EPS)?
JSPR trailing twelve-month (TTM) diluted EPS is $-3.63, reflecting +19.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Jasper Therapeutics, Inc.'s net income?
Jasper Therapeutics, Inc. (JSPR) trailing twelve-month net income is $-56M as of 2025. Earnings grew +19.2% year-over-year.
Is JSPR profitable?
JSPR is not currently profitable on a TTM basis, reporting a net loss of $-56M. Net margin is N/A. Investors should monitor for a return to profitability.
What is JSPR's earnings growth rate?
JSPR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are JSPR's profit margins?
Jasper Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -230.3%.
Is JSPR growing earnings?
Yes, JSPR earnings are accelerating — EPS growth of +19.2% exceeds the 5-year CAGR of N/A. TTM net income reached $-56M. Earnings momentum is strengthening.
What was JSPR's best earnings year?
Jasper Therapeutics, Inc.'s highest annual net income on record is $-5M, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were JSPR's earnings last quarter?
JSPR's most recent reported quarter was Q1 2026. Net income was $-1M with diluted EPS of $-0.08. For a full breakdown of all quarters, see the quarterly earnings table on this page.